Objective: The incidence of cerebrovascular accidents (CVA) occurring perinatally is relatively high and aspects of the multifactorial pathophysiology remain unclear. Elevated homocysteine concentrations have been shown to be associated with an increased risk for CVA in children and even in newborns. We studied the possible homocysteine lowering effect of folinic acid in newborns. Method: We included 37 newborns in our prospective randomized folinic acid (given as 5-formyltetrahydrofolate) intervention study from patients admitted to our neonatal intensive care unit (18 controls, 19 intervention group). We measured total homocysteine (tHcy) and plasma folate concentrations at three time points (baseline, 1 and 2 weeks after intervention). The intervention group was treated with folinic acid (70 mg/kg/day) for 2 weeks. We calculated median concentrations (25th and 75th percentiles). Results: Median tHcy concentrations at the three time points did not differ from each other in the control group nor in the intervention group. We also could not observe different tHcy concentrations between both groups. Plasma folate concentrations increased in the intervention group (mean increase 167% (95% confidence interval (CI) À291, 625)) compared with control group (mean increase À12% (95% CI À132, 108)), P for treatment effect: 0.03. Conclusion: We could not demonstrate a homocysteine lowering effect of folinic acid administration in newborns. This indicates that one carbon metabolism in newborns differs form adults. Cobalamin might be a better strategy to lower tHcy concentrations in newborns.
Introduction
The overall incidence of cerebrovascular accident (CVA) in childhood is very low (approximately 3/100 000 per year) (Raju et al., 2007) . In strong contrast, CVA's occurring in the perinatal period have a much higher incidence (Raju et al., 2007) . It is estimated that the incidence of ischemic perinatal stroke is 1 in 2300-5000 births and accounts for 30% of children affected with cerebral palsy (Raju et al., 2007) . Of major importance is the fact that about 10% of newborns admitted to a neonatal intensive care unit suffer from a CVA. Known potential risk factors of the latter are prematurity, asphyxia, hypoglycemia, polycythemia, catheter-related complications, infectious factors, persistent fetal circulation, intra-uterine growth restriction and maternal factors such as diabetes or antiphospholipid syndrome (Grabowski et al., 2007; Raju et al., 2007) . Independent of the possible cause CVA can result in significant morbidity, varying from mild hemiplegia to severe cerebral palsy, sensory impairments, mental retardation and even death. Yet aspects of the multifactorial pathophysiology leading to CVA in the newborn remain unclear and in about one third of cases no obvious cause or risk factor can be diagnosed (Akar et al., 2001) .
Elevated total homocysteine (tHcy) concentrations have been found to be a risk factor in adults for the development of cardiovascular disease and venous and arterial thrombosis including CVA. Elevated tHcy concentrations can, amongst others, be caused by genetic polymorphisms of the methylenetetrahydrofolate reductase gene and/or cystathionine b synthase gene (van der Linden et al., 2006) . Non-genetic factors such as folate, vitamin B12 and/or B6 intake, age, sex, estrogen, alcohol consumption and smoking can also influence tHcy (Ueland and Refsum, 1989; Gellekink et al., 2005; Verhoef and de Groot, 2005) .
In adults, tHcy can be easily, safely and quickly lowered by 0.2 to 5 mg folic acid each day, even in the absence of elevated tHcy concentrations (Brattstrom et al., 1988; den Heijer et al., 1998; van Oort et al., 2003) . Current intervention trials show negative results from secondary prevention regarding the cardiovascular risk reduction. Meta-analyses on CVA and elevated tHcy concentrations however suggest that B-vitamin supplementation may lower the risk of CVA by approximately 20-25% (Homocysteine Lowering Trialists ' Collaboration, 2000; Herrmann et al., 2007) . Wang et al. (2007) performed a meta-analysis on folic acid supplementation in relation to stroke and observed an overall decrease of 18%. Furthermore, their results suggested that folic acid supplementation can significantly reduce the risk of stroke in primary prevention (relative risk 0.75 (0.62, 0.90)).
van Beynum et al. (1999) demonstrated that elevated tHcy concentrations increased the risk of ischemic stroke in Dutch children aged 0-18 years. Sirachainan et al. (2006) found an odds ratio (OR) of 8.2 (95% confidence interval (CI) 1.4-47.2) for developing ischemic stroke in patients aged p18 years with elevated tHcy concentrations. In a previous study, we described significantly higher mean tHcy concentrations in 24 newborn infants with stroke compared with 94 healthy newborn infants ) (Hogeveen et al., 2002) . These studies suggest that elevated tHcy concentrations are also a risk factor for CVA in children and newborns. As the incidence of CVA in patients admitted to a neonatal intensive care unit is relatively high, we conducted the first prospective randomized folinic acid intervention study in newborns to study whether this risk factor can be modified in this age category.
Subjects and methods

Subjects
We conducted a prospective randomized intervention study. All newborns admitted to the neonatal intensive care unit in the University Medical Centre Nijmegen, The Netherlands in 2003 were eligible to the study. Those with midline defects, extracorporal membrane oxygenation treatment, overt renal failure or blood transfusion were excluded.
After written informed consent was obtained, the subjects were randomized for receiving daily folinic acid supplement (intervention group) or no supplement (control group). No supplement was given because a placebo effect is unlikely in this age category. Parents, nurses and physicians were not blinded to group assignment. Patients received normal medical care during this research project. Evaluations of cerebral ultrasounds and/or scans were performed by physicians not involved in this project and unaware of supplementation. Randomization was centralized but not computerized. This means that for each participant an envelope was drawn by the research assistant at the time of inclusion. These envelopes, filled with 'intervention' or 'control' notes were mixed thoroughly before they were stored in a box. This study was approved by the local ethics committee (Committee on Ethics in Research with Human Subjects Nijmegen).
Data collection
Clinical data from the newborn were obtained daily from the medical record. We obtained data on gestational age, birth weight, newborn sex, days on ventilator, laboratory results, sepsis/meningitis, intraventricular bleeding or stroke. When newborns were transferred to another hospital during the study period daily folinic acid supplementation (intervention group) was continued and blood samples were drawn as planned.
Blood sampling
Blood was drawn either capillary or arterially during routine blood sampling. Samples were taken within 48 h after birth (baseline), at day 8±1 day (1 week) and at day 15±1 day (2 weeks). EDTA blood (0.5-1.0 ml) was placed on ice immediately and centrifuged within 2 h. Plasma and cell pellets were separated and stored at À30 1C until analysis.
Folinic acid supplementation
Folinic acid was given for 2 weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv, Haarlem, The Netherlands). This solution was administered either intravenously (first week) or orally. To lower tHcy in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 mgram/kg/day for our newborns.
Biochemical analyses
Plasma tHcy was determined in EDTA plasma by an automated high-performance liquid chromatography method with reverse-phase separation and fluorescent detection (Gilson 232-401 sample processor, Gilson Medical Electronics, Middleton, WI, USA; Spectra Physics 8800 solvent delivery system and Spectra Physics LC 304 fluorometer, Spectra Physics, San Jose, CA, USA) as described by te Poele-Pothoff et al. (1995) .
Plasma folate was determined in EDTA plasma in a competitive immunoassay (Immulite 2000, Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA).
Statistical analysis
Results were presented as median values with their 25th and 75th percentiles. Differences between groups were determined by Mann-Whitney test or independent samples t-test where appropriate. Statistical analyses were all performed using SPSS 14.0 for Windows.
Results
We have included 37 newborns in our study (19 intervention group, 18 control group). Characteristics of both groups are presented in Table 1 . Newborns were admitted because of prematurity, respiratory, infectious or circulatory problems. They were between 26 and 40 weeks of gestational age and between 600 and 3500 grams. Parameters were not significantly different at baseline between the intervention and control group. Figure 1 shows individual plasma tHcy and folate concentrations at baseline and after 1 and 2 weeks from both groups. Because of the transfer to another hospital, death, loss of samples and/or too little amount of blood sampled data were not complete for all newborns. In Table 2 , median tHcy and folate concentrations at three time points in both groups and mean change between baseline and 2 weeks are shown. Neither plasma tHcy nor folate concentrations were correlated to gestational age, birth weight or creatinine at the three time points. Plasma tHcy concentrations did not differ significantly at the three time points in the intervention group nor the control group. Plasma tHcy concentrations in the intervention and control group were not different. Plasma folate concentrations at 2 weeks in the intervention group were significantly higher compared with concentrations at 2 weeks in the control group.
Discussion
In contrast to our expectation, we could not demonstrate a homocysteine lowering effect of folinic acid administration in newborns in this prospective randomized intervention study. This unexpected finding might be influenced by folinic acid dose, time of blood sampling, way of administration or other factors. However, it could also indicate that homocysteine metabolism in the neonate may differ from metabolism later in life.
We are fully aware that this is a small study with only 37 patients included. Still, as data on folate and homocysteine in newborns are scarce, we believe that our results add information on one carbon metabolism in this age category. We have performed an intervention study without placebo group because a placebo effect is unlikely in this age category. We strongly do believe that this did not influence our results, as every newborn received routine neonatal intensive care. Furthermore, cerebral ultrasounds and/or scans were judged by physicians who were not aware of this study. Fuller et al. (1992) routinely supplemented preterm infants with 1 mg folate orally (pteroylglutamic acid) to encourage growth rates in erythroblastotic newborns without gross side effects. This is, on a body weight basis, around 250 times the recommended amount for adults and around 5-20 times the amount recommended at that time for (premature) infants. On the basis of the results from other studies, they extrapolated that 0.05-0.2 mg/day folate appears safe for preterm infants which is comparable to our dose. In adults, folic acid supplementation (0.4-5 mg per day) reduces tHcy between 13 and 25% even in the absence of folate deficiency or elevated tHcy concentrations (Homocysteine Lowering Trialists' Collaboration, 2005) . In a meta-analysis by the Homocysteine Lowering Trialists' Collaboration the effect of folic acid supplementation was more profound with incremental doses of folic acid, higher pretreatment tHcy concentrations or lower pretreatment folate concentrations (Homocysteine Lowering Trialists' Collaboration, 2005) . In this study, we supplemented the newborns with 0.07 mg/kg/day folinic acid, which is comparable with 5 mg folic acid a day in adults. We considered this dose to be high enough to expect an effect in newborns, as in adults 0.2 mg folic acid or higher a day decreases tHcy concentrations. Blood samples were obtained at baseline and 1 and 2 weeks after birth. As several authors have described a significant tHcy concentration reduction with folic acid within 14 days in adults, we considered this a sufficient period of time to study if folinic acid decreases tHcy concentrations (Brattstrom et al., 1988; Wilcken et al., 1988) . Folic acid supplementation was given as 5-formyltetrahydrofolate (folinic acid), an active form of folate containing a one carbon group for metabolism. Several studies show that folinic acid given either intravenously or orally was as effective or even better than folic acid in lowering plasma tHcy concentrations (Touam et al., 1999; Buccianti et al., 2001;  Homocysteine lowering effect of folinic acid M Hogeveen et al Hauser et al., 2001; Yango et al., 2001) . Ducloux et al. (2002) showed a similar tHcy lowering effect of folinic acid administered intravenously compared with orally supplemented folinic acid. They also observed a similar tHcy lowering effect of intravenously administered folinic acid compared with folic acid in adults. On the basis of these results and the possibility of intravenous administration, we considered folinic acid as the best way to study its lowering effect on tHcy in newborns. Data on the pattern of neonatal tHcy and plasma folate concentrations are scarce. Median tHcy between 6.3-6.8 mmol/l and mean tHcy between 6.1-7.8 mmol/l have been described in umbilical cord blood or the first days after birth (Hongsprabhas et al., 1999; Minet et al., 2000; GuerraShinohara et al., 2002; Bjorke Monsen and Ueland, 2003; Refsum et al., 2004; Couto et al., 2007; Karademir et al., 2007) . At day 7 Jyothi et al. (2007) describe median tHcy concentrations of 6.3 mmol/l (p25-p75:2.8-8.4 mmol/l), whereas Fokkema et al. (2002) observed mean tHcy concentrations of 6.4 ± 2.6 mmol/l at day 10 and 6.7 ± 2.4 mmol/l at day 20). Our data are comparable with these results. Hongsprabhas et al. (1999) describe an increase in mean tHcy concentrations in the first 2 weeks of life. In our study, tHcy concentrations do not differ between baseline and 1 and 2 weeks after birth neither in the control group nor in the intervention group.
With respect to folate, mean neonatal plasma concentrations of about 25 nmol/l have been described (Minet et al., 2000; Guerra-Shinohara et al., 2002; Refsum et al., 2004; Schulpis et al., 2004; Couto et al., 2007) , which is comparable with our results. These relatively high plasma folate concentrations in newborns compared with adults might explain the loss of correlation with tHcy concentrations in this age category.
The past few years, several authors describe a stronger relationship in infants between cobalamin and tHcy than between plasma folate and tHcy (Minet et al., 2000; Bjorke Monsen et al., 2001; Fokkema et al., 2002; Guerra-Shinohara et al., 2002; Molloy et al., 2002) . Bjorke Monsen et al. (2001) describe even an absence of correlation between plasma folate and tHcy (r ¼ À0.06) in 173 apparently healthy newborns at day 4, whereas correlation between cobalamin and tHcy was high (r ¼ À0.52). Minet et al. (2000) also describe a better correlation between cobalamin and tHcy in comparison to plasma folate and tHcy (r ¼ À0.64 and r ¼ 0.30 respectively). van Beynum et al. (2005) suggest that homozygosity for MTHFR 677C4T polymorphism only influences homocysteine concentrations in children (0-19 years) with low folate status. Taken together, cobalamin might be a more important determinant of tHcy than plasma folate in infants and thus cobalamin treatment may be a better choice to decrease tHcy concentrations in infants and newborns (Bjorke-Monsen et al., 2008) .
During our study period, four children suffered from a CVA. Although this study was not designed to explore the effect of folinic acid supplementation on the incidence of CVA, only one patient from the intervention group had a CVA compared with three newborns in the control group.
In conclusion, we could not observe a homocysteine lowering effect of folinic acid supplementation in a 2 weeks intervention study in newborns. This observation was unexpected because similar conditions in adults substantially lower tHcy concentrations. Our findings indicate that one carbon metabolism in newborns differs from adults. Recent data suggest that cobalamin is a stronger determinant of tHcy concentrations in newborns. Thus, cobalamin supplementation offers an attractive alternative and further studies should focus on cobalamin.
